Gastroenterology

In part A of the trial, 60% of patients treated with dupilumab weekly met the primary endpoint of histologic remission, compared to 5% of the placebo group.

There was no differences observed in total weight loss at both 6 and 18 months in the fecal microbiota transplantation and placebo groups.

Anita Afzali, MD, MPH, MHCM, FACG, AGAF, explores clinical implications of newer therapies for Crohn’s disease in the real-world setting.

Jennifer Seminerio, MD, discusses long-term outcomes and clinical remission rates for patients on an IL/23 inhibitor for Crohn’s disease.

The results show significant LSM relative reductions compared to pooled placebo in aspartate aminotransferase for pegozafermin 3 mg once weekly, 27 mg once weekly, and 36 mg once every 2 weeks.

Dr Miguel Regueiro comments on the safety and efficacy of approved IL-23 inhibitors and IL-12/23 inhibitors for the treatment of Crohn’s disease.

Jennifer Seminerio, MD, and Bincy P. Abraham, MD, MS, AGAF, FACG, share their perspective on the use of IL-12/23 inhibitors in clinical practice for the management of Crohn’s disease.

In 2021, the USPSTF changed guidance on colorectal cancer screenings, reducing the recommended age of a colonoscopy from 50 to 45 years.

Drs Bincy P. Abraham, Miguel Regueiro, David P. Hudesman, Anita Afzali, and Jennifer Seminerio provide insight on approaching the optimal therapy for patients with Crohn’s disease in the frontline and second-line settings.

Drs Miguel Regueiro, Jennifer Seminerio, Anita Afzali, and David Hudesman review currently available biologic therapies for moderate-to-severe Crohn’s disease and the evolution of the disease treatment landscape.

Prometheus Biosciences is expected to begin phase 3 trials for the treatment in 2023.

The male gender was positively associated with a higher risk of serious infection at month 12 and penetrating disease behavior was positively associated with 12-month treatment persistence.

The product is administered as a single dose and is manufactured using the stool of qualified donors.

Dr Bincy P. Abraham leads a discussion on factors to consider when selecting a therapy for the management of Crohn’s disease.

Experts in gastroenterology review goals of therapy for the management of Crohn’s disease, utilizing a treat-to-target approach for treatment, and the importance of shared decision-making.

Dr Anita Afzali and Dr Bincy P. Abraham review the diagnostic workup for Crohn’s disease and challenges in diagnosing the disease.

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, provide insight on the pathophysiology of Crohn’s Disease (CD), associated risk factors, and diagnosis of disease.

The treatment is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, can possibly reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery.

In the QUSAR study, 80% of patients treated with guselkumab achieved a clinical response.

For safety, 24.1% of the entire study population experienced adverse events, with 18 participants developing tuberculosis.

The investigators found that depression increased the odds of systemic steroid administrations, the use of 2 or more molecular targeted drugs, and surgery in patients with ulcerative colitis.

New pooled phase 3 data presented at ACAAI 2022 supports the FDA's approval of dupilumab for eosinophilic esophagitis.

More than 70% of patients treated with RBX2660 were recurrence free at the 8 week mark.

The efficacy of H pylori treatments has waned in recent years, largely because of clarithromycin resistance.

The approval of risankizumab represents the first ever IL-23 approved by the FDA for IBD.